Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Tax Provisions (2020 - 2025)

Keros Therapeutics (KROS) has disclosed Tax Provisions for 4 consecutive years, with -$1.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions fell 604.67% year-over-year to -$1.5 million, compared with a TTM value of $4.9 million through Dec 2025, up 1527.67%, and an annual FY2025 reading of $4.9 million, up 1527.67% over the prior year.
  • Tax Provisions was -$1.5 million for Q4 2025 at Keros Therapeutics, down from -$1.4 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $10.0 million in Q1 2025 and bottomed at -$2.2 million in Q2 2025.
  • Average Tax Provisions over 3 years is $899250.0, with a median of $6000.0 recorded in 2021.
  • The sharpest move saw Tax Provisions soared 129.07% in 2021, then tumbled 604.67% in 2025.
  • Year by year, Tax Provisions stood at $2.0 million in 2021, then plummeted by 84.99% to $300000.0 in 2024, then crashed by 604.67% to -$1.5 million in 2025.
  • Business Quant data shows Tax Provisions for KROS at -$1.5 million in Q4 2025, -$1.4 million in Q3 2025, and -$2.2 million in Q2 2025.